Frontlight ResearchEarly access
SuspendedPhase 1
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
Key facts
- Who runs it
- Innovent Biologics (Suzhou) Co. Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- Phase
- Phase 1
- People taking part
- 120 people, planned
- Started
- 30 Sept 2020
- Ended
- 20 Aug 2024
- Type of study
- Interventional
- Treatments tested
- IBI188+azacitidine
- Record updated
- 16 February 2023
- Why it stopped
- Suspended for changes in development strategy
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- MDS subjects with higher risk
- Age ≥ 18 years old
- Eastern Cooperative Oncology Group score of 0~1
- Not suitable for or refuse to receive HSCT
- Newly diagnosed MDS subjects
- Adequate organ function
- Subjects should take effective contraceptive measures
- Must sign the Informed Consent Form (ICF), and be able to follow all study procedures
Who cannot take part
- Therapy-related MDS (t-MDS), myeloproliferative neoplasm (MPN)- transformed MDS,MDS/MPN
- Subjects who have received chemotherapy
- Prior exposure to any anti-CD47 or anti-SIRPα agents
- Subject who has transformed from MDS to AML
- MDS subjects with lower risk
- Subjects participating in another interventional clinical study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study is to evaluate safety and efficacy of IBI188 in combination with azacitidine (AZA) as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic syndrome
The group in the trial
- IBI188+azacitidineTreatment being tested
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome
- Record updated
- 16 February 2023